arrow
Y

Yasmeen Fleifil

cincinnati children's hospital medical center
H指数:3
被引数:54

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Detection of Low Levels of DNAJB1::PRKACA Fusion KinaseRequires the Utilization of Sensitive Assays and CarefulMethodological Planning. Reply to Palaz et al. Independent Multi-Cohort RNA-Seq Analysis Does Not Support Recurrent DNAJB1::PRKACA Fusion in Hepatoblastoma or Biliary Atresia. Comment on “Fleifil et al. DNAJB1-PKAc Kinase Is Expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways. Cancers 2025, 17, 83”

检测低水平DNAJB1::PRKACA融合激酶需要利用敏感的检测方法和谨慎的方法学规划。回复给Palaz等人。独立的多个队列RNA测序分析不支持在肝母细胞瘤或胆道闭锁中存在复发性DNAJB1::PRKACA融合。评论“Fleifil等人。DNAJB1-PKAc激酶在患有儿科肝癌的年轻患者中表达并增强致癌通路。Cancers 2025, 17, 83”

Cancers
IF4.4
2026-08-280
OA
Fusion DNAJB1::PRKACA in Non-Fibrolamellar Cancer Cases. Reply to Arif et al. Global Re-Analysis Confirms Absence of the DNAJB1::PRKACA Fusion in Hepatoblastoma. Comment on “Fleifil et al. DNAJB1-PKAc Kinase Is Expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways. Cancers 2025, 17, 83”

融合DNAJB1::PRKACA在非纤维板层样癌病例中。回复Arif et al. 全局重分析证实DNAJB1::PRKACA融合在肝母细胞瘤中不存在。评论“Fleifil et al. DNAJB1-PKAc激酶在年轻儿科肝癌患者中表达并增强致癌通路。Cancers 2025, 17, 83”。

Cancers
IF4.4
2026-03-120
OAAI